{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7"},{"groupId":"OG001","value":"31.1"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5"},{"groupId":"OG001","value":"67.2"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.6"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"0.0"}]}],"title":"3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"The Eastern Cooperative Oncology Group Performance Status (ECOG PS) score classified participants according to their functional impairment, with scores ranging from 0 to 4. ECOG PS: 0 = fully active, able to carry on all pre-disease performance without restriction; 1 = restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work; 2 = ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3 = capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = completely disabled, cannot carry on any self-care, totally confined to bed or chair. A higher score means a worse functional status.","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.","id":"OG000","title":"AG-120"},{"description":"Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who were randomized, with the treatment group designated according to the randomization.","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status","type":"SECONDARY","unitOfMeasure":"percentage of participants"}